Outlook Therapeutics Appoints Kevin Lundquist as New CFO, Succeeding Lawrence Kenyon

Outlook Therapeutics announced a transition in its executive leadership, appointing Kevin Lundquist as its new Chief Financial Officer, Treasurer, and principal financial officer, effective September 1, 2026. Mr. Lundquist will succeed Lawrence A. Kenyon, who is stepping down from his roles and the Board of Directors. The company stated that Mr. Kenyon's departure is not the result of any disagreement with the company.

Key Details

• New CFO Appointment: Kevin Lundquist will assume the role of CFO on September 1, 2026. He brings extensive experience from previous CFO roles at CapsoVision Inc. and Abzena Biologics, Inc., and finance leadership positions at Revance, Roche, and Abbott Laboratories.
• New CFO Compensation: Mr. Lundquist's employment agreement includes an annual base salary of $450,000, a target annual bonus of 50% of his base salary, and an initial stock option grant to purchase 500,000 shares of common stock.
• Executive Transition: Lawrence A. Kenyon will continue in a non-executive role through September 30, 2026, to ensure an orderly transition. He will also resign from the Board of Directors by this date, after which the Board's size will be reduced to eight members.